Prime Medicine (PRME) Shares Outstanding (2021 - 2026)

Prime Medicine has reported Shares Outstanding for 6 years, with the latest figure at $180.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 37.71% year-over-year to $180.6 million; the trailing twelve-month figure through Mar 2026 stood at $180.6 million (up 37.71% YoY), and the FY2025 full-year result was $180.5 million, up 37.63% from the prior year.
• Shares Outstanding for Q1 2026 stood at $180.6 million, roughly flat from $180.5 million in the prior quarter.
• The five-year high for Shares Outstanding was $180.6 million in Q1 2026, with the low at $33.5 million in Q2 2022.
• Historically, Shares Outstanding has averaged $111.6 million across 5 years, with a median of $120.0 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding soared 199.9% — and 2023, when it advanced 0.17%.
• Prime Medicine's Shares Outstanding stood at $97.2 million in 2022, then climbed by 0.17% to $97.4 million in 2023, then surged by 34.69% to $131.2 million in 2024, then surged by 37.63% to $180.5 million in 2025, then gained by 0.06% to $180.6 million in 2026.
• The last three Shares Outstanding figures came in at $180.6 million (Q1 2026), $180.5 million (Q4 2025), and $180.3 million (Q3 2025), per Business Quant data.